首页> 美国卫生研究院文献>Aging (Albany NY) >MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma
【2h】

MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma

机译:MiR-223-3p通过下调SLC4A4在透明细胞肾细胞癌中促进细胞增殖和转移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs) are known to affect the occurrence and progression of cancer. We therefore evaluated the involvement of miR-223-3p in renal cell cancer. MiR-223-3p was highly expressed in clear cell renal cell cancer tissues. Clear cell renal cell cancer patients with higher miR-223-3p expression had higher tumor stages and grades and poorer prognoses. In renal cancer cells, overexpression of miR-223-3p enhanced cell proliferation and metastasis, while inhibition of miR-223-3p reduced the malignant capacity of the cells. MiR-223-3p was found to bind directly to solute carrier family 4, member 4 (SLC4A4) mRNA, thereby reducing SLC4A4 mRNA and protein expression. SLC4A4 overexpression restrained cell proliferation and metastasis by suppressing Kirsten rat sarcoma viral oncogene (KRAS) expression in renal cancer cells. SLC4A4 expression correlated negatively with miR-223-3p expression in patient samples. Given that miR-223-3p suppressed the SLC4A4/KRAS axis, miR-223-3p gene therapy could be an effective treatment for renal cancer.
机译:已知MicroRNA(miRNA)会影响癌症的发生和发展。因此,我们评估了miR-223-3p与肾细胞癌的关系。 MiR-223-3p在透明细胞肾细胞癌组织中高表达。 miR-223-3p表达较高的透明细胞肾细胞癌患者的肿瘤分期和分级较高,预后较差。在肾癌细胞中,miR-223-3p的过表达增强了细胞的增殖和转移,而对miR-223-3p的抑制则降低了细胞的恶性能力。发现MiR-223-3p直接与溶质载体家族4的成员4(SLC4A4)mRNA结合,从而降低SLC4A4 mRNA和蛋白质表达。 SLC4A4过表达通过抑制肾癌细胞中的Kirsten大鼠肉瘤病毒致癌基因(KRAS)表达来抑制细胞增殖和转移。患者样品中SLC4A4表达与miR-223-3p表达负相关。鉴于miR-223-3p抑制了SLC4A4 / KRAS轴,miR-223-3p基因治疗可能是治疗肾癌的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号